FAILURE TO ACHIEVE CASTRATE LEVELS OF TESTOSTERONE DURING LUTEINIZING HORMONE RELEASING HORMONE AGONIST THERAPY: THE CASE FOR MONITORING SERUM TESTOSTERONE AND A TREATMENT DECISION ALGORITHM
- 1 September 2000
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 164 (3 Part 1) , 726-729
- https://doi.org/10.1016/s0022-5347(05)67290-4
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessmentUrology, 1999
- Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancerUrology, 1999
- TIME TO NORMALIZATION OF SERUM TESTOSTERONE AFTER 3-MONTH LUTEINIZING HORMONE-RELEASING HORMONE AGONIST ADMINISTERED IN THE NEOADJUVANT SETTING: IMPLICATIONS FOR DOSING SCHEDULE AND NEOADJUVANT STUDY CONSIDERATIONJournal of Urology, 1998
- Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate CancerNew England Journal of Medicine, 1998
- Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancerClinical Therapeutics, 1996
- A New Long Acting Formulation of the Luteinizing Hormone-Releasing Hormone Analogue, Goserelin: Results of Studies in Prostate CancerJournal of Urology, 1996
- Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trialUrology, 1995
- Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic CarcinomaBritish Journal of Urology, 1991
- Zoladex versus orchiectomy in treatmentof advanced prostate cancer: a randomized trialUrology, 1991
- A Controlled Trial of Leuprolide with and without Flutamide in Prostatic CarcinomaNew England Journal of Medicine, 1989